ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
This approval will enable radiopharmacies and hospitals using ARTMS' QIS® cyclotron technology and associated targets to produce multi-Curies of 68Ga for use with Gozellix®. The expanded distribution radius and increased dose production capacity, compared to existing gallium-based PET tracers, will facilitate broader and more equitable access. In addition, use of ARTMS' technology is being expanded internationally where regulatory submissions are in preparation. Pharmaceutical companies will be able to reference ARTMS' standardized isotope production technology with their approved drugs, helping to localize and simplify manufacturing.
Chad Watkins, General Manager ARTMS and Isotope Strategy, Telix, said, 'This DMF reference represents a significant milestone for ARTMS, our partners and customers. The combination of these innovative technologies reflects Telix's commitment to working in partnership to reach more patients with 68Ga-PSMA-11, where and when they need it.'
The QIS® forms part of ARTMS' 'turnkey' solution for customers that encompasses in-house manufactured targets and chemistry processing of isotopes, as well as DMF preparation and filing support. This makes large scale isotope production for hospitals and radiopharmaceutical distributors with cyclotrons significantly more attainable than with other existing technologies.
ARTMS will continue to support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients. In addition, ARTMS' portfolio of advanced cyclotron technologies has application for Telix and select partners in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At).
For further information please contact:
Chad Watkins Telix Pharmaceuticals LimitedGeneral Manager of ARTMS & Isotope StrategyEmail: Chad.Watkins@TelixPharma.com
Kevin ReimerTelix ARTMS, Inc.VP Global Sales and MarketingEmail: Kevin.Reimer@TelixPharma.com
About Telix ARTMS, Inc.
Based in Burnaby, British Columbia, Canada, Telix ARTMS, Inc. (ARTMS) is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world's most-used diagnostic imaging isotopes. ARTMS' flagship product, the QUANTM Irradiation System® (QIS®), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS was acquired by Telix Pharmaceuticals in April 20242. For more information on QIS® and ARTMS, please follow us on X @ARTMS_TLX and LinkedIn and visit www.artms.ca/
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA3.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: kyahn.williamson@telixpharma.com
Legal Notices
You should read this announcement together with Telix risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.
_______________________
1 A DMF is a submission to FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products.2 Telix ASX disclosure 11 April 2024.3 Telix ASX disclosure 21 March 2025.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
HOKA Launches the Mafate 5, Featuring New Rocker Integrity Technology for the Ultimate Trail Performance
GOLETA, Calif.--(BUSINESS WIRE)-- HOKA®, a division of Deckers Brands (NYSE: DECK) introduces the Mafate 5, the latest evolution of the brand's iconic trail franchise. Engineered to help ultra-runners conquer trails with confidence, the Mafate 5 delivers enhanced durability, adaptability, and cushioning for long-haul endurance on rough terrain. The Mafate 5 is available now on and at authorized dealers worldwide. [ Link to Campaign Imagery] The Mafate 5 debuts the all-new Rocker Integrity Technology — an innovative breakthrough that helps maintain rocker shape over multiple miles, this curved plate made from light, pliable TPU delivers snap with every step. Placed between a firmer SCF EVA layer directly underfoot and a softer CMEVA foam layer beneath it, the Mafate 5 boasts a suspended ride experience unlike its predecessors and redefines traditional dual-density foam systems. This new technology allows the shoe to absorb uneven terrain and adapt to the trail, while maintaining a responsive foot strike and efficient toe-off. The outsole utilizes Vibram® Megagrip with Traction Lug technology, ensuring grip on any surface. The upper provides durable 360-degree protection constructed with an all-new flow molded TPU cage, with a nod to the HOKA UTMB® Mont-Blanc course map etched within the design. The Mafate 5 is the brand's first-ever shoe featuring an ankle gaiter integration system, sold separately. The option for an added gaiter will allow runners additional protection to shield themselves from trail debris for uninterrupted performance. FOR THE LONG RUN 'We know the unique challenges ultra-runners face when on the trail. That's why we've developed a shoe that meets their specific needs, offering durability to withstand the harshest environments, adaptability to adjust to varying terrains, and comfort to keep them going,' said Bekah Broe, Senior Director of Product, Performance Footwear at HOKA. 'We know every stride counts, and our updates to the Mafate 5 will give runners the confidence and support they need to tackle the trail, no matter how grueling it gets out there.' To celebrate the launch of the Mafate 5, built for the unique rigors of the HOKA UTMB® Mont-Blanc course, HOKA is inviting runners to experience the magic of UTMB® at their own pace with a nationwide Stava challenge. From August 8 through September 12, users who run 109.6 miles (176.4 km), the full distance of the HOKA UTMB® Mont-Blanc, will earn a digital finisher's badge and be entered to win the grand prize: an entry and all expenses paid trip to next year's HOKA UTMB® Mont-Blanc or a UTMB® World Series race of their choice, plus a Mafate 5 shoe and gear prize pack. Five additional winners will receive the Mafate 5 and a full HOKA trail running apparel pack. The Mafate 5 has an 8mm heel-to-toe drop and weighs in at 10.1 oz/285g for a Women's size 8 and 11.7 oz/332.3g for a Men's Size 10. The Mafate 5 is available from August 1, 2025, at and at authorized dealers worldwide. MSRP $185. See here for imagery. About HOKA® HOKA® is one of the fastest-growing performance footwear and apparel brands in history. Conceived in the mountains, HOKA footwear delivers an unprecedented combination of enhanced cushioning and support for a uniquely smooth ride. Every day, HOKA pushes the innovation and design of its footwear and apparel by teaming up with a deep roster of world champions, taste makers and everyday athletes. From finish lines to everyday life, HOKA fans love the brand for its bold and unexpected approach, and its belief in the power of humanity to create change for a better world. HOKA empowers a world of athletes to fly over the earth. For more information, visit or follow @HOKA. #FlyHumanFly About Deckers Brands Deckers Brands is a global leader in designing, marketing, and distributing innovative footwear, apparel, and accessories developed for both everyday casual lifestyle use and high-performance activities. The Company's portfolio of brands includes UGG®, HOKA®, Teva®, and AHNU®. Deckers Brands products are sold in more than 50 countries and territories through select department and specialty stores, Company-owned and operated retail stores, and select online stores, including Company-owned websites. Deckers Brands has over 50 years of history building niche footwear brands into lifestyle market leaders attracting millions of loyal consumers globally. For more information, please visit
Business Wire
a minute ago
- Business Wire
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's management will host an informational webinar on Bio-Rad's Droplet Digital™ PCR (ddPCR™) product portfolio on Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time). The event will include a presentation followed by a Q&A session with analysts hosted by Bio-Rad's President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. To participate, dial (800) 715-9871 within the U.S. or (+1) (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the event, and the accompanying slide presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,500 employees, and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit
Business Wire
a minute ago
- Business Wire
PGIM expands fixed income ETF suite with launch of three actively managed corporate bond ETFs
NEWARK, N.J.--(BUSINESS WIRE)-- PGIM, 1 the $1.39 trillion global investment management business of Prudential Financial, Inc. (NYSE: PRU), has launched three new actively managed fixed income ETFs: the PGIM Corporate Bond 0–5 Year ETF (PCS), PGIM Corporate Bond 5–10 Year ETF (PCI), and PGIM Corporate Bond 10+ Year ETF (PCL). 'These ETFs are designed to meet the growing demand for investing in high-quality corporate fixed income securities.' Share The new ETFs each seek to provide total return through a combination of current income and capital appreciation with cost-effective access to investment-grade corporate bonds across the maturity spectrum. PGIM Corporate Bond 0–5 Year ETF (PCS) invests primarily in investment-grade corporate bonds with maturities of less than five years at a 0.20% net expense ratio. PGIM Corporate Bond 5–10 Year ETF (PCI) invests primarily in investment-grade corporate bonds with maturities between five and 10 years, offering intermediate-term exposure at a 0.25% net expense ratio. PGIM Corporate Bond 10+ Year ETF (PCL) invests primarily in long-duration investment-grade corporate bonds with maturities of 10 years or more at a 0.25% net expense ratio. PCS, PCI, and PCL are attractively priced, with net expense ratios ranking top quartile amongst active mutual funds and ETFs within their respective Morningstar categories. This pricing reflects PGIM's commitment to delivering actively managed expertise at highly competitive costs. 2 'These ETFs are designed to meet the growing demand for investing in high-quality corporate fixed income securities,' said Stuart Parker, PGIM's head of global wealth. 'This launch reflects our commitment to bringing a diverse set of actively managed fixed income solutions to market for clients in additional wrappers.' All three ETFs are actively managed and aim to maintain a weighted average portfolio duration within one year of their respective Bloomberg U.S. Corporate Bond Index benchmarks. The funds are listed on the Cboe BZX Exchange. Rajat Shah, PGIM's co-head of U.S. Investment Grade Corporate Bonds, added, 'These ETFs leverage PGIM's deep expertise in credit research and active portfolio management to uncover value while seeking to deliver consistent, long-term returns for our clients. By offering targeted maturity exposure with active management, our solutions can help investors better align their bond allocations with risk and return objectives.' The launch of PCS, PCI, and PCL expands PGIM's growing ETF platform, which now includes 13 fixed income ETFs and more than 50 equity, multi-asset and buffer ETFs. PGIM is the 11th-largest active ETF provider, with $17.1 billion in AUM across the ETF platform. 3 ABOUT PGIM PGIM is the global asset management business of Prudential Financial, Inc. (NYSE: PRU). In 41 offices across 19 countries, our more than 1,450 investment professionals serve both retail and institutional clients around the world. As a leading global asset manager with $1.39 trillion in assets under management, 4 PGIM is built on a foundation of strength, stability, and disciplined risk management. Our multi-affiliate model allows us to deliver specialized expertise across key asset classes with a focused investment approach. This gives our clients a diversified suite of investment strategies and solutions with global depth and scale across public and private asset classes, including fixed income, equities, real estate, private credit, and other alternatives. For more information, visit Prudential Financial, Inc. (PFI) of the United States is not affiliated in any manner with Prudential plc, incorporated in the United Kingdom, or with Prudential Assurance Company, a subsidiary of M&G plc, incorporated in the United Kingdom. For more information please visit 1 The term PGIM as used in this announcement includes PGIM Investments LLC, an indirect, wholly owned subsidiary of Prudential Financial, Inc. 2 Source: Morningstar as of June 30, 2025. Net expense ratios are ranked against active ETFs and mutual funds (institutional share class only). Morningstar categories: PCS: Short-Term Bond Category, PCI: Corporate Bond Category; PCL: Long Duration Bond Category. 3 As of June 30, 2025. 4 As of March 31, 2025. Consider a fund's investment objectives, risks, charges and expenses carefully before investing. The prospectus and summary prospectus contain this and other information about the fund. Contact your financial professional for a prospectus and summary prospectus. Read them carefully before investing. Investment products are distributed by Prudential Investment Management Services LLC, member FINRA and SIPC. PGIM Investments is a registered investment advisor and investment manager. PGIM Fixed Income is an affiliate of PGIM and is a Prudential Financial company. © 2025 Prudential Financial, Inc. and its related entities. PGIM, PGIM Investments, PGIM Fixed Income and the PGIM logo are service marks of Prudential Financial, Inc. and its related entities, registered in many jurisdictions worldwide. Investing in exchange-traded funds (ETFs) involves risks. Some ETFs have more risk than others. The investment return and principal value will fluctuate, and shares when sold may be worth more or less than the original cost, and it is possible to lose money. The Funds are actively managed ETFs and thus do not seek to replicate the performance of a specified index. ETF shares are not individually redeemable from the Funds. Shares may only be redeemed directly from the Fund by Authorized Participants in Creation Units. Fixed income investments are subject to credit, market, and interest rate risks (including duration risk and prepayment risk), and their value will decline as interest rates rise; call and redemption risk, where the issuer may call a bond held by the Funds for redemption before it matures and the Funds may lose income; liquidity risk, which exists when particular investments are difficult to sell; and emerging markets risk, which exposes the Funds to greater volatility and price declines. Risks of investing in the Funds include but are not limited to the following: Exchange-traded funds (ETFs) may trade at a premium or discount to net asset value or lack an active trading market, may be less liquid and may be subject to brokerage commission or other charges. As an actively managed ETF, the Fund is subject to risks involved with: actively and frequently trading; ETF shares trading risk (including the risk of the shares trading at a premium or discount to net asset value or the lack an active trading market); authorized participant concentration risk; the risk of transacting in cash versus in-kind; as well as the cost of buying or selling shares through a broker. Fixed income investments are subject to credit risk, market risk and interest rate risk (including duration risk, prepayment risk and extension risk) and may also be subject to call and redemption risk, which is the risk that the issuer may call a bond held by the Fund before maturity and the Fund may not be able to reinvest at the same rate; credit and counterparty risk, which is the risk that the issuer or guarantor of a debt security, or the counterparty (the party on the other side of the transaction) to a derivatives contract or other financial contract to meet its financial obligations will affect the value of the security or derivative; and liquidity risk, which exists when particular investments are difficult to sell. The Fund may invest in foreign securities, which generally involve more risk than investing in U.S. issuers, including political, legal, and economic uncertainty. The Fund may be subject to management risk, where the value of your investment may decrease if judgments by the subadviser are incorrect; economic and markets event risk, meaning that events in global financial markets could result in high market volatility, market disruption and geopolitical risks, meaning that international wars or conflicts and geopolitical developments including terrorist attacks and outbreaks of infectious diseases could negatively impact interest rates, market volatility and security pricing, and market risk, where the value of investments may decrease and securities markets are volatile. Large shareholders could subject the Fund to large-scale redemption risk. Derivatives may carry market, credit, and liquidity risks. Diversification does not assure a profit or protect against loss in declining markets. These risks may increase the Fund's share price volatility. There is no guarantee the Fund's objective will be achieved. Risks are more fully explained in the Fund's prospectus. Investment products are not insured by the FDIC or any federal government agency, may lose value, and are not a deposit of or guaranteed by any bank or any bank affiliate. CONTROL # 4692657
